Drug · DIN 02230420
IMITREX
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 22, 2002; first marketed February 19, 1997.
- Drug Identification Number (DIN)
- 02230420
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Spray
- Route
- Nasal
- Therapeutic class (ATC)
- Sumatriptan N02CC01
- Class
- Human
- Record last updated
- June 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SUMATRIPTAN (SUMATRIPTAN HEMISULFATE) | 20 MG | ACT |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 18, 2001: NOC 2563New Drug Submission (NDS) · Change in manufacturer name
- December 24, 1996: NOC 4681Supplement to a New Drug Submission (SNDS) · New dosage form
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “imitrex”. A notice may cover another product or only some lots: read it to see what it covers.
- Imitrex (2013-11-01)November 21, 2013 · Drugs · Product safety · Type I
Other DINs named IMITREX
- DIN 02212188 · Marketed
- DIN 02230418 · Marketed